13 February 2019 - - US-based healthcare technology company ZappRx will work with Israel-based Teva Respiratory, LLC, in support of their specialty respiratory medication, the company said.

The joint project will provide a more efficient approach to prescribe, obtain, and administer therapy necessary for patients to better manage their disease and symptoms.

ZappRx's cloud-based platform streamlines what is currently a multi-step, manual prescribing process, often involving numerous platforms for each of several treatments, into a single, digitally-enabled format. This allows providers who treat severe asthma to focus more on patient care.

The company said it streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for ordering specialty drugs, including pharmacy information, payer/prior authorisation requirements, and relevant clinical history.

ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls.

The platform currently is live in Pulmonary (including Cystic Fibrosis, Pulmonary Arterial Hypertension, and Idiopathic Pulmonary Fibrosis), Severe Asthma, Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn's Disease and Ulcerative Colitis).

As the company grows, ZappRx plans to expand into other areas, including Rheumatology, Neurology, and Oncology.
Connect with ZappRx on Twitter and LinkedIn.